Fate Therapeutics (FATE) Tops Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Leerink Partners Remains Bullish as Fate Therapeutics (FATE) Plans to Initiate ProTmune Study
March 4, 2016 9:49 AM ESTLeerink Partners maintained an Outperform rating on Fate Therapeutics (NASDAQ: FATE), and cut the price target to $4.00 (from $8.00), following the company's 4Q earnings report. FATE's reported EPS of ($0.26) was slightly better than estimate' of ($0.28). The company also announced that it anticipates initiating the Phase I/II study of ProTmune in... More
